Bio Pharma Dive
MARCH 13, 2025
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.
Rethinking Clinical Trials
MARCH 13, 2025
Speaker F. Perry Wilson, MD MSCE Associate Professor of Medicine and Public Health Director, Clinical and Translational Research Accelerator Yale University New Haven, CT Slides Keywords Electronic Alerts; Acute Kidney Injury; Action Team Key Points Acute Kidney Injury (AKI), or abrupt decline in kidney function, is common, affecting about 15% of hospitalized patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
MARCH 12, 2025
Sean Mann In this Friday’s PCT Grand Rounds, Sean Mann of RAND will present “Spillover Due to Constraints on Care Delivery: A Potential Source of Bias in Pragmatic Clinical Trials.” The Grand Rounds session will be held on Friday, March 14, 2025, at 1:00 pm eastern. Mann is a senior policy analyst at RAND. Join the online meeting. The post March 12, 2025: In This Week’s PCT Grand Rounds, Spillover as a Potential Source of Bias in Pragmatic Trials appeared first on Rethink
Bio Pharma Dive
MARCH 11, 2025
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
MARCH 14, 2025
The venture aims to advance MeiraGTxs Parkinsons gene therapy through Phase III trials with up to $430m in funding from Hologen.
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 12, 2025
(Laura Leyshon/Getty Images) If you head to the shops to buy bread, you’ll face a variety of different options. But it can be hard to work out the difference between all the types on sale. For instance, you might have a vague idea that wholemeal or wholegrain bread is healthy. But what’s the difference?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
MARCH 12, 2025
Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia vera (PV).
XTalks
MARCH 11, 2025
Arvinas and Pfizer have reported positive Phase III VERITAC-2 results in a trial of 624 patients across 26 countries, demonstrating that vepdegestrant (ARV-471) monotherapy significantly improves progression-free survival in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer.
Medical Xpress
MARCH 15, 2025
Artificial intelligence can transform medicine in a myriad of ways, including its promise to act as a trusted diagnostic aide to busy clinicians.
Drug Patent Watch
MARCH 12, 2025
The Unseen Heroes of Generic Drugs: Stability Testing 101 As a consumer, have you ever stopped to think about the rigorous process that goes into bringing a generic version of your favorite medication to market? It's not just a matter of copying a formula and slapping a new label on it. Behind the scenes, generic drug manufacturers are working tirelessly to ensure that their products are safe, effective, and identical to their branded counterparts.
Bio Pharma Dive
MARCH 11, 2025
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
Pharmaceutical Technology
MARCH 11, 2025
AWSs framework will speed up the analysis of ElevateBios large protein datasets, hinting at promising drug candidates.
XTalks
MARCH 17, 2025
On March 7, 2025, Advanced Biomed Inc. raised $6.56 million in its IPO and began trading on Nasdaq under the ticker ADVB. The biotech firm, which develops semiconductor-based microfluidic technology for early cancer detection, issued 1.64 million shares at $4 each, with an option to purchase an additional 246,000 shares within 45 days. Current Share Price: Established in 2014, Advanced Biomed has developed a proprietary microfluidic platform that functions as a compact laboratory on a chip.
Medical Xpress
MARCH 15, 2025
Monkeys infected with Ebola can be cured with a pill, according to a new study out Friday that could pave the way for more practical, affordable treatments in humans.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
ACRP blog
MARCH 17, 2025
This is a sponsored message. To grow your business, negotiate and collect fair payment for your work by understanding its true costs before budget discussions. This includes all direct and indirect costs, and typically covers: Personnel costs: salaries, overtime, training, and additional staffing if needed. Facility costs: not only facility space, maintenance, utilities, and equipment, but also any additional space or modifications needed for the study.
Bio Pharma Dive
MARCH 14, 2025
The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting that's typically held was canceled last month.
Pharmaceutical Technology
MARCH 11, 2025
The multi-year manufacturing deal with CordenPharma will secure future supply of VK2735 if it goes to market.
XTalks
MARCH 14, 2025
Novo Nordisks investigational obesity combination drug, CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg), underperformed in its latest clinical trial, leading to a dip in the companys share price. In response to the trial outcomes, Novos shares declined by approximately 8% this week. Novo shared the latest data from the Phase III REDEFINE 2 trial evaluating the drug in overweight or obese patients with type 2 diabetes.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
MARCH 17, 2025
Collaboration brings remote care to cancer patients
Drug Patent Watch
MARCH 13, 2025
Navigating the Complex World of Biosimilar Supply Chains As the demand for biosimilars continues to grow, so do the challenges associated with their supply chains. From manufacturing and quality control to distribution and regulatory compliance, the stakes are high for pharmaceutical companies looking to bring these life-changing treatments to market.
Bio Pharma Dive
MARCH 13, 2025
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
Pharmaceutical Technology
MARCH 17, 2025
Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
XTalks
MARCH 13, 2025
In 2025, as market pressures intensify and companies refocus on core strategic priorities, medical device and medtech companies have been forced to make tough decisions regarding their workforces. These developments come amid a broader nationwide trend of workforce realignment, with both private and public entities, including the FDA’s recent rehires amid mass layoffs, adapting to ongoing pressures.
Pharma Times
MARCH 11, 2025
Oxford Medical Products targets overweight individuals
Pharma Marketing Network
MARCH 17, 2025
Table of Contents Understanding the Importance of HCP Engagement in Pharma Marketing Key Marketing Strategies for Pharma Brands to Reach HCPs Optimizing Digital and Paid Media Strategies for Pharma Marketing Measuring Success: Tracking HCP Engagement and ROI Understanding the Importance of HCP Engagement in Pharma Marketing Engaging healthcare professionals (HCPs) effectively is a top priority for pharmaceutical brands.
Bio Pharma Dive
MARCH 17, 2025
Study results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant in treating certain blood cancers.
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Pharmaceutical Technology
MARCH 13, 2025
Emergent has entered a strategic financial investment agreement with Swiss Rockets to support the latters biotech portfolio.
XTalks
MARCH 13, 2025
Perfuze advances stroke care with FDA 510(k) clearance for its new Zipline access catheters. Designed to support the delivery of large aspiration catheters during neurointerventional procedures, the device aims to enhance physicians ability to quickly remove blood clots from patients suffering from acute ischemic stroke a condition where every minute matters.
Pharma Times
MARCH 11, 2025
CervoMed's therapy demonstrates significant improvement in patients
Medical Xpress
MARCH 15, 2025
Children under eight should not drink slushy ice drinks containing glycerol, researchers have warned after a string of hospitalizations in the UK and Ireland.
Expert insights. Personalized for you.
302 
Let's personalize your content